Ube Industries, Inc.

Shigeyuki Kono

Noriaki Iwase

Tomio Kimura

Shigeru Ushiyama

Makoto Okudo

Masaaki Matoyama

Yusuke Shiraishi

Masahiro Kojima

Yasuhiro Aga

Satoshi Umezaki

Hiroshi Nishida

Hidetoshi Sunamoto

Eiji Okanari

Masaaki Ito

Sayaka Ogi

Hirofumi Matsunaga

Kenji Nishikawa

Takashi Matsushita

Kazuhiro Onuma

Masayuki Tanaka

Hayato Nishiyama

The present invention provides a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, the two Rs each independently represents a Calkyl group, or are bonded together to form a Calkylene group, A represents a Caryl group (which may be a substituted Caryl group), Z represents a hydrogen atom or a Calkyl group (which may be a substituted Caryl group), or A and Z may be bonded to each other, with the group represented by Z—N-A forming a bicyclic fused heteroaryl group, which may be substituted, and R, R, and Reach independently represents a linear or branched Calkyl group that may be substituted.]

Dihydropyrrolopyrazole derivative

Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: wherein Lis an optionally substituted Calkylene group or the like, Lis a single bond or the like, Lis a single bond or the like, R, R, and Rare each independently an optionally substituted Calkyl group or the like, Ris a hydrogen atom or the like, and Ris a hydrogen atom or the like.

Substituted dihydropyrrolopyrazole compound

The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a Calkyl group or the like; and R, Rand Reach independently represent an optionally substituted linear or branched Calkyl group. 

Substituted dihydropyrrolopyrazole derivative

A novel &#x3b1;-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; Ris the same or different, and represents a halogen atom, or a C-Calkyl group; Rrepresents a hydrogen atom, or a C-Calkyl group; p represents an integer of 0 to 5; V represents CRwherein Rrepresents a hydrogen atom, an amino group, a nitro group, or a C-Calkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.

Halogen-substituted heterocyclic compound

Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein Lis an optionally substituted Calkylene group or the like, Lis a single bond or the like, Lis a single bond or the like, R, R, and Rare each independently an optionally substituted Calkyl group or the like, Ris a hydrogen atom or the like, and Ris a hydrogen atom or the like.

The invention provides a novel &#x3b1;-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament. The salt is represented by the general formula (I):  

Halogen-substituted heterocyclic compound salt

A novel &#x3b1;-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided.

Growing community of inventors

Ube, Japan

Shigeyuki Kono